Evidence map›Paper›PMID 38646349›Full record

ArticleCureus2024

Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease.

Toyoshi Yanagihara, Hiroaki Ogata, Asami Mori, Masako Kadowaki, Yuki Moriuchi, Akiko Ishimatsu, Junji Otsuka, Kazuhito Taguchi, Atushi Moriwaki, Makoto Yoshida

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Toyoshi YanagiharaRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Hiroaki OgataRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Asami MoriPharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Masako KadowakiInfectious Diseases, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Yuki MoriuchiRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Akiko IshimatsuRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Junji OtsukaRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Kazuhito TaguchiRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Atushi MoriwakiRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Makoto YoshidaRespiratory Medicine, National Hospital Organization Fukuoka National Hospital, Fukuoka, JPN.
Fukuoka Higashi Medical Center · JPFukuoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of

Indexed as

amikacin liposome inhalation suspensionguideline-based therapymycobacterium avium complexnontuberculous mycobacteria (ntm)refractory mac pulmonary disease

Identifiers

PMID38646349
PMCPMC11032006
OpenAlexW4393043784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.